- As a promising grower, OncoMed is leveraging on the “more shots on goal” strategy. Despite earlier missed clinical outcomes, the company is brewing stellar molecules that are approaching their binaries.
- Anti-TIGIT is an interesting franchise being investigated in combination with an anti-PD1. We’re most interested in navicixizumab, a multi-dimensional molecule being assessed in combination with the standard chemotherapy.
- If the later-stage clinical outcomes are favorable as we prognosticated, the company can become a target for acquisition.
Read More: https://seekingalpha.com/article/4175755-oncomed-pharmaceuticals-assessing-prospect-potential-robust-winner